{
  "data": {
    "id": "stat_GMYPTHCR25PSS2A2G385G7T53M",
    "url": "https://statorigin.org/stat/stat_GMYPTHCR25PSS2A2G385G7T53M",
    "indicator": {
      "slug": "branded-medicines-sales-clawback-cap",
      "name": "Branded medicines sales clawback cap",
      "definition": "Statutory or agreed ceiling on revenue clawback rates applied to branded prescription medicine sales."
    },
    "industry": [
      {
        "slug": "pharmaceuticals",
        "name": "Manufacture of basic pharmaceutical products and pharmaceutical preparations",
        "isic": "C21",
        "is_primary": true
      }
    ],
    "region": {
      "code": "GB",
      "name": "United Kingdom",
      "type": "country"
    },
    "period": {
      "start": "2026-09-08",
      "end": "2026-09-08",
      "type": "point"
    },
    "value": 15,
    "value_text": "15 per cent",
    "unit": "percent",
    "currency": null,
    "scale": "1",
    "value_type": "actual",
    "source": {
      "org": "Association of the British Pharmaceutical Industry",
      "org_short_name": "ABPI",
      "org_url": "https://www.abpi.org.uk",
      "org_tier": 2,
      "document_title": "Green shoots for UK pharma investment, but delivery will decide whether they take root",
      "document_url": "https://www.abpi.org.uk/media/news/2026/august/green-shoots-for-uk-pharma-investment-but-delivery-will-decide-whether-they-take-root/",
      "document_type": "press_release",
      "locator": "UK competitive weaknesses",
      "quote": "Despite a new 15 per cent cap on branded medicines sales clawback rates, the UK's rate on newer medicines remains higher than every other comparator country in the analysis, several of which operate no clawback system at all.",
      "published_date": null,
      "accessed_at": "2026-09-17",
      "license": "see-source",
      "url_status": "ok"
    },
    "verification": "verified",
    "verified_by": "seed:auto-extract-v1",
    "verified_at": "2026-09-17T07:16:01.811Z",
    "confidence": 0.9,
    "is_secondhand": false,
    "supersedes": null,
    "superseded_by": null,
    "is_current": true,
    "citation": {
      "apa": "Association of the British Pharmaceutical Industry. (2026). Green shoots for UK pharma investment, but delivery will decide whether they take root. Retrieved September 17, 2026, from https://www.abpi.org.uk/media/news/2026/august/green-shoots-for-uk-pharma-investment-but-delivery-will-decide-whether-they-take-root/. Via StatOrigin, https://statorigin.org/stat/stat_GMYPTHCR25PSS2A2G385G7T53M",
      "bibtex": "@misc{abpi2026brandedg7t53m,\n  author       = {{Association of the British Pharmaceutical Industry}},\n  title        = {Green shoots for UK pharma investment, but delivery will decide whether they take root},\n  year         = {2026},\n  howpublished = {StatOrigin, https://statorigin.org},\n  url          = {https://statorigin.org/stat/stat_GMYPTHCR25PSS2A2G385G7T53M},\n  note         = {Original source: https://www.abpi.org.uk/media/news/2026/august/green-shoots-for-uk-pharma-investment-but-delivery-will-decide-whether-they-take-root/. Accessed September 17, 2026.}\n}"
    },
    "updated_at": "2026-09-17T07:16:01.811Z",
    "contested_by": [],
    "related": []
  },
  "meta": {
    "attribution": "Data from StatOrigin (https://statorigin.org), CC BY 4.0. Attribution required.",
    "license": "https://creativecommons.org/licenses/by/4.0/",
    "docs": "https://statorigin.org/docs/api",
    "total": 1
  }
}